Strategic Initiatives, Executive Transitions, and Strengthened Portfolios to Increase Shareholder Value - Research Report on Trius, HCA, Alere, UHS, and Bio-Reference

NEW YORK, August 5, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Trius Therapeutics, Inc. (NASDAQ: TSRX), HCA Holdings, Inc. (NYSE: HCA), Alere Inc. (NYSE: ALR), Universal Health Services Inc. (NYSE: UHS), and Bio-Reference Laboratories Inc. (NASDAQ: BRLI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Trius Therapeutics, Inc. Research Report

On July 30, 2013, Trius Therapeutics Inc. (Trius) and Cubist Pharmaceuticals Inc. (Cubist) jointly announced a definitive agreement under which Cubist will acquire all outstanding shares of Trius for $13.50 per share in cash or nearly $707 million on a fully diluted basis. Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius, said, "This transaction culminates years of intense work by the Trius team to achieve this outcome, and our shareholders are being rewarded for their involvement and support of the company." According to the Companies, the agreement includes each Trius stockholder to receive one Contingent Value Right (CVR), entitling the holder to receive an additional cash payment of up to $2.00 for each share they own if certain commercial sales milestones are achieved. The Full Research Report on Trius Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []


HCA Holdings, Inc. Research Report

On July 29, 2013, HCA Holdings, Inc. (HCA) announced the retirement of Richard M. Bracken as Chairman and Chief Executive Officer of the Company, who will now transition as the Chairman of the Board at the end of 2013. R. Milton Johnson will assume the position of HCA's Chief Executive Officer, effective that same time. Bracken joined HCA in 1981 and has held several executive leadership roles within the Company while Johnson has served the Company for 31 years. Johnson was named a member of the Company's Board of Directors in 2009 and assumed his current role as President in 2011. The Full Research Report on HCA Holdings, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []


Alere Inc. Research Report

On July 31, 2013, Alere Inc. (Alere) announced its Q2 2013 financial results posting net revenue of $764 million compared to $700.5 million in Q2 2012. Net loss attributable to common stockholders of the Company was $65.9 million or $0.81 per diluted share, compared to $18.2 million or $0.23 in Q2 2012. Non-GAAP adjusted net income per diluted share was $0.64 compared to $0.48 in Q2 2012. Ron Zwanziger, Chairman, Chief Executive Officer and President of Alere, said, "We are pleased to report a very strong quarter for Alere and continued progress against the three-point strategic plan that we implemented in November 2012. In particular, our currency adjusted organic growth rate for our professional diagnostics segment, excluding changes in our U.S. Triage and influenza revenues, was 8.6%, reflecting the strength of our highly-differentiated portfolio across the globe. In addition, our combined adjusted research and development and selling, general and administrative expenses decreased as a percentage of revenue by 230 basis points from the prior year quarter. Our growth rate in the quarter, coupled with disciplined expense control, demonstrates our continued momentum and commitment to enhancing value for our shareholders." The Full Research Report on Alere Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []


Universal Health Services Inc. Research Report

On July 25, 2013, Universal Health Services, Inc. (UHS) announced its Q2 2013 financial results, reporting net income attributable to UHS of $151.8 million or $1.53 per diluted share compared to $197.6 million or $1.10 per diluted share in Q2 2012. Reported net revenues were up 6.5% YoY to $1.8 billion. The Acute Care Services net revenues increased 4.9% YoY, whereas its Behavioral Health Care Services net revenues increased 3.2% YoY. For H1 2013, the Company reported net revenues of $3. 7 billion, compared to $3.5 billion in H1 2012. The Full Research Report on Universal Health Services Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []


Bio-Reference Laboratories Inc. Research Report

On July 22, 2013, Bio-Reference Laboratories Inc. (Bio-reference) announced that it has signed a licensing agreement with the University of Washington to make, and all other related properties to become a business unit of Bio-Reference. Vice President of Marketing for Bio-Reference, Amar Kamath, commented, "We recognized that has been providing a community service since molecular genetics was in its infancy, and we're pleased to be preserving and maintaining this valuable resource free-of-charge to users." According to the Company, has been a main resource for physicians, geneticists and genetic counselors seeking comprehensive information about testing for inherited disorders and genetic counseling services since 1992. The Full Research Report on Bio-Reference Laboratories Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []



  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
  5. For any urgent concerns or inquiries, please contact us at [email protected].
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.


Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Investors' Reports

Suggested Articles

Q32 Bio raised $60 million to push its lead antibody through the clinic and bolster its pipeline and the technology behind it.

Sanofi is teaming up with Merck while AstraZeneca taps Arcus as the future of cancer work is very much made together.

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.